First-line chemotherapy plus ICIs or bevacizumab in advanced non-squamous NSCLC without EGFR mutations or ALK fusions. Supplementary materials
datasetposted on 2022-03-09, 08:39 authored by Lili Jiang, Hui GUO, Shen Yuan, Kejun Nan, Jia Zhang, Nanzheng Chen, Yu YAO, Min Jiao, WenJuan Wang, Qinyang Wang, Ziyang Mao, Luying Geng, Panpan Jiang
Figure S1: Forest plots for results of pairwise meta-analyses for OS, PFS in all population.
Figure S2: Network meta-analysis of specific regimens of PFS in random effect model or excluded IMpower150.
Figure S3: Subgroup analysis of OS and PFS for specific regimens.
Table S1: Quality assessment: risk of bias according to Cochrane Collaboration’s tool
Table S2: Comparisons of the fit of consistency and inconsistency models using deviance information criteria.
Table S3: Heterogeneity analysis of direct and indirect outcomes.
Table S4: Rank probability of PFS for specific regimens excluded IMpower150 study.
Table S5: Bayesian ranking results of network meta-analysis of different treatment models in whole population.
Table S6: Bayesian ranking results of network meta-analysis of different treatment models in subgroups.
Table S7: Rank probability of OS, PFS, ORR and 3-5 grade treatment related AEs for specific regimens in whole population.
Table S8: Rank probability of OS and PFS for specific regimens in subgroups.
Table S9: Literature search strategies